The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Open accessAbstract
Alternative Role for EZH2: Epigenetic regulators are implicated in cancer progression and proposed as therapeutic targets. Xu et al. (p. 1465 ; see the Perspective by Cavalli ) report that EZH2 (Enhancer of zeste homolog 2), a factor previously thought to exert its oncogenic function primarily as part of the polycomb repressive complex, acts through a distinct mechanism in cells of castration-resistant prostate cancer. Rather than exclusively silencing gene expression through histone methylation, EZH2 acts as a transcriptional coactivator. The activation function of EZH2 plays a critical role in the growth of castration-resistant prostate cancer cells, which could be relevant in future drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Self-citationSmyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
Polycomb silencers control cell fate, development and cancer
Sparmann, A., & van Lohuizen, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1991 · Cited by 1,303
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3
Cao, R., & Zhang, Y. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.02.001 · Cited by 914
Cited by
UALCAN: An update to the integrated cancer data analysis platform
Chandrashekar, D. S., Karthikeyan, S. K., Korla, P. K., Patel, H., Shovon, A. R., Athar, M., Netto, G. J., Qin, Z. S., Kumar, S., Manne, U., et al. (2022) · Neoplasia · doi:10.1016/j.neo.2022.01.001 · Cited by 2,473
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Non-small-cell lung cancers: a heterogeneous set of diseases
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3775 · Cited by 1,942
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 910
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 806
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Simon, J. A., & Kingston, R. E. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.02.013 · Cited by 733
Mondal, T., Subhash, S., Vaid, R., Enroth, S., Uday, S., Reinius, B., Mitra, S., Mohammed, A., James, A. R., Hoberg, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms8743 · Cited by 665
Sequence determinants of improved CRISPR sgRNA design
Xu, H., Xiao, T., Chen, C.-H., Li, W., Meyer, C. A., Wu, Q., Wu, D., Cong, L., Zhang, F., Liu, J. S., et al. (2015) · Genome Research · doi:10.1101/gr.191452.115 · Cited by 625
Self-citationTargeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Dardenne, E., Beltran, H., Benelli, M., Gayvert, K., Berger, A., Puca, L., Cyrta, J., Sboner, A., Noorzad, Z., MacDonald, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.005 · Cited by 559
Epigenetic balance of gene expression by Polycomb and COMPASS families
Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524
Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K.-C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 523
Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease
DuPage, M., & Bluestone, J. A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.18 · Cited by 513
Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 426
Self-citationTargeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
Hartman, Z. C., Poage, G. M., den Hollander, P., Tsimelzon, A., Hill, J., Panupinthu, N., Zhang, Y., Mazumdar, A., Hilsenbeck, S. G., Mills, G. B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4524-t · Cited by 409
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kim, K. H., Kim, W., Howard, T. P., Vazquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 406
Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2014) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 370
Self-citationDuPage, M., Chopra, G., Quiros, J., Rosenthal, W. L., Morar, M. M., Holohan, D., Zhang, R., Turka, L., Marson, A., & Bluestone, J. A. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.007 · Cited by 332
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
Kim, W., Bird, G. H., Neff, T., Guo, G., Kerenyi, M. A., Walensky, L. D., & Orkin, S. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1331 · Cited by 338
Xie, H., Xu, J., Hsu, J. H., Nguyen, M., Fujiwara, Y., Peng, C., & Orkin, S. H. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.10.001 · Cited by 322
SET for life: biochemical activities and biological functions of SET domain-containing proteins
Herz, H.-M., Garruss, A., & Shilatifard, A. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.09.004 · Cited by 314
Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19
Hua, J. T., Ahmed, M., Guo, H., Zhang, Y., Chen, S., Soares, F., Lu, J., Zhou, S., Wang, M., Li, H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.014 · Cited by 315
Self-citationPolycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
Kim, J., Lee, Y., Lu, X., Song, B., Fong, K.-W., Cao, Q., Licht, J. D., Zhao, J. C., & Yu, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.035 · Cited by 306
Regulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
Karantanos, T., Evans, C. P., Tombal, B., Thompson, T. C., Montironi, R., & Isaacs, W. B. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.049 · Cited by 285
Self-citationJarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation
Sanulli, S., Justin, N., Teissandier, A., Ancelin, K., Portoso, M., Caron, M., Michaud, A., Lombard, B., da Rocha, S. T., Offer, J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.020 · Cited by 281
Ito, T., Teo, Y. V., Evans, S. A., Neretti, N., & Sedivy, J. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.002 · Cited by 265
A new world of Polycombs: unexpected partnerships and emerging functions
Schwartz, Y. B., & Pirrotta, V. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3603 · Cited by 276
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Groner, A. C., Cato, L., de Tribolet-Hardy, J., Bernasocchi, T., Janouskova, H., Melchers, D., Houtman, R., Cato, A. C. B., Tschopp, P., Gu, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.012 · Cited by 263
Self-citationRecent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer
Guo, H., Ahmed, M., Zhang, F., Yao, C. Q., Li, S., Liang, Y., Hua, J., Soares, F., Sun, Y., Langstein, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3637 · Cited by 226
Self-citationEED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Hsu, J. H.-R., Rasmusson, T., Robinson, J., Pachl, F., Read, J., Kawatkar, S., O’ Donovan, D. H., Bagal, S., Code, E., Rawlins, P., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.004 · Cited by 202
Huang, S., Wang, Z., Zhou, J., Huang, J., Zhou, L., Luo, J., Wan, Y. Y., Long, H., & Zhu, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2395 · Cited by 185
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14922 · Cited by 127
Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602079113 · Cited by 87
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Rizq, O., Mimura, N., Oshima, M., Saraya, A., Koide, S., Kato, Y., Aoyama, K., Nakajima-Takagi, Y., Wang, C., Chiba, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2735 · Cited by 83
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif
Jehle, K., Cato, L., Neeb, A., Muhle-Goll, C., Jung, N., Smith, E. W., Buzon, V., Carbó, L. R., Estébanez-Perpiñá, E., Schmitz, K., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.534859 · Cited by 53
“Thereafter ChIP was performed as previously described (34, 35) using following antibodies: anti-AR (N20, Santa Cruz), Bag-1L (36) and HA-tag (ab9110, Abcam).”
MethodLima-Fernandes, E., Murison, A., da Silva Medina, T., Wang, Y., Ma, A., Leung, C., Luciani, G. M., Haynes, J., Pollett, A., Zeller, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09309-4 · Cited by 50
McLaughlin-Drubin, M., & Munger, K. (2013) · Viruses · doi:10.3390/v5051231 · Cited by 28
Metadata
- Authors
- Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., Xu, H., Cato, L., Thornton, J. E., Gregory, R. I., Morrissey, C., Vessella, R. L., Montironi, R., Magi-Galluzzi, C., Kantoff, P. W., Balk, S. P., Liu, X. S., & Brown, M.
- Venue
- Science
- Published
- 2012-12-14
- Volume
- 338
- Issue
- 6113
- Pages
- 1465-1469
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2053116646
- Cited by
- 875
- References
- 45
- FWCI
- 40.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.